{
  "ticker": "ABBV",
  "export_date": "2025-11-15T01:16:26.067003",
  "article_count": 2,
  "articles": [
    {
      "original_title": "Surged Following Strong Results and Increased Guidance",
      "original_body": "In its third-quarter 2025 investor letter, Carillon Eagle Growth &amp; Income Fund highlighted stocks such as AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical co… [+151 chars]",
      "cleaned_title": "Surged Following Strong Results and Increased Guidance",
      "cleaned_body": "In its third-quarter 2025 investor letter, Carillon Eagle Growth Income Fund highlighted stocks such as AbbVie Inc. NYSEABBV. AbbVie Inc. NYSEABBV is a research-based biopharmaceutical co 151 chars",
      "cleaned_text": "Surged Following Strong Results and Increased Guidance. In its third-quarter 2025 investor letter, Carillon Eagle Growth Income Fund highlighted stocks such as AbbVie Inc. NYSEABBV. AbbVie Inc. NYSEABBV is a research-based biopharmaceutical co 151 chars",
      "tokens": {
        "original": [
          "surged",
          "following",
          "strong",
          "results",
          "and",
          "increased",
          "guidance",
          "in",
          "its",
          "third-quarter",
          "2025",
          "investor",
          "letter",
          ",",
          "carillon",
          "eagle",
          "growth",
          "income",
          "fund",
          "highlighted",
          "stocks",
          "such",
          "as",
          "abbvie",
          "inc.",
          "nyseabbv",
          ".",
          "abbvie",
          "inc.",
          "nyseabbv",
          "is",
          "a",
          "research-based",
          "biopharmaceutical",
          "co",
          "151",
          "chars"
        ],
        "filtered": [
          "surged",
          "following",
          "strong",
          "results",
          "increased",
          "guidance",
          "third-quarter",
          "2025",
          "investor",
          "letter",
          ",",
          "carillon",
          "eagle",
          "growth",
          "income",
          "fund",
          "highlighted",
          "stocks",
          "abbvie",
          "inc.",
          "nyseabbv",
          ".",
          "abbvie",
          "inc.",
          "nyseabbv",
          "research-based",
          "biopharmaceutical",
          "co",
          "151",
          "chars"
        ],
        "lemmatized": [
          "surge",
          "follow",
          "strong",
          "result",
          "increase",
          "guidance",
          "third-quarter",
          "2025",
          "investor",
          "letter",
          ",",
          "carillon",
          "eagle",
          "growth",
          "income",
          "fund",
          "highlight",
          "stock",
          "abbvie",
          "inc.",
          "nyseabbv",
          ".",
          "abbvie",
          "inc.",
          "nyseabbv",
          "research-based",
          "biopharmaceutical",
          "co",
          "151",
          "char"
        ]
      },
      "features": {
        "entities": {
          "PERSON": [
            "Carillon Eagle Growth",
            "Income Fund"
          ],
          "ORGANIZATION": [
            "AbbVie Inc.",
            "NYSE"
          ],
          "GPE": [
            "Strong",
            "Guidance"
          ]
        },
        "financial_keywords": {
          "positive": [
            "surge",
            "strong",
            "growth",
            "high"
          ],
          "negative": [],
          "neutral": [
            "quarter"
          ]
        },
        "numbers": [
          "2025",
          "151"
        ],
        "percentages": [],
        "dates": [],
        "top_words": [
          [
            "abbvie",
            2
          ],
          [
            "inc.",
            2
          ],
          [
            "nyseabbv",
            2
          ],
          [
            "surge",
            1
          ],
          [
            "follow",
            1
          ],
          [
            "strong",
            1
          ],
          [
            "result",
            1
          ],
          [
            "increase",
            1
          ],
          [
            "guidance",
            1
          ],
          [
            "third-quarter",
            1
          ]
        ],
        "stats": {
          "num_entities": 6,
          "num_positive_keywords": 4,
          "num_negative_keywords": 0,
          "num_neutral_keywords": 1,
          "num_numbers": 2,
          "num_percentages": 0,
          "num_dates": 0
        }
      },
      "stats": {
        "num_sentences": 3,
        "num_words": 38,
        "avg_words_per_sentence": 12.67,
        "num_unique_words": 34
      },
      "processed_at": "2025-11-14T03:28:51.817054",
      "preprocessing_version": "1.0",
      "article_id": "c06a44ac59a91f47",
      "title": "Surged Following Strong Results and Increased Guidance",
      "description": "In its third-quarter 2025 investor letter, Carillon Eagle Growth & Income Fund highlighted stocks such as AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company. The one-month return of AbbVie Inc. (NYSE:ABBV) was -0.46…",
      "body": "In its third-quarter 2025 investor letter, Carillon Eagle Growth &amp; Income Fund highlighted stocks such as AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical co… [+151 chars]",
      "source": "Biztoc.com",
      "source_api": "newsapi",
      "source_priority": 3,
      "url": "https://biztoc.com/x/ae97ceba25b59c05",
      "author": "finance.yahoo.com",
      "published_at": "2025-11-12T14:41:32Z",
      "scraped_at": "2025-11-13T22:21:10.044020",
      "ticker": "AAPL",
      "raw_text": "Surged Following Strong Results and Increased Guidance In its third-quarter 2025 investor letter, Carillon Eagle Growth & Income Fund highlighted stocks such as AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company. The one-month return of AbbVie Inc. (NYSE:ABBV) was -0.46… In its third-quarter 2025 investor letter, Carillon Eagle Growth &amp; Income Fund highlighted stocks such as AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical co… [+151 chars]",
      "sentiment_score": null,
      "sentiment_label": null,
      "image": null,
      "category": null,
      "tickers_mentioned": [
        "ABBV"
      ],
      "ticker_confidence": {
        "ABBV": 80
      },
      "ticker_contexts": {
        "ABBV": [
          "Carillon Eagle Growth & Income Fund highlighted stocks such as **AbbVie** Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company.",
          "& Income Fund highlighted stocks such as AbbVie Inc. (NYSE:ABBV). **AbbVie** Inc. (NYSE:ABBV) is a research-based biopharmaceutical company. The one-month return",
          "(NYSE:ABBV) is a research-based biopharmaceutical company. The one-month return of **AbbVie** Inc. (NYSE:ABBV) was -0.46… In its third-quarter 2025 investor letter,",
          "Carillon Eagle Growth &amp; Income Fund highlighted stocks such as **AbbVie** Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical co…",
          "&amp; Income Fund highlighted stocks such as AbbVie Inc. (NYSE:ABBV). **AbbVie** Inc. (NYSE:ABBV) is a research-based biopharmaceutical co… [+151 chars]"
        ]
      },
      "is_duplicate": false,
      "duplicate_of": null,
      "similarity_score": 0.0
    },
    {
      "original_title": "AbbVie (ABBV) Surged Following Strong Results and Increased Guidance",
      "original_body": "Carillon Tower Advisers, an investment management company, released its Carillon Eagle Growth &amp; Income Fund third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&… [+2462 chars]",
      "cleaned_title": "AbbVie ABBV Surged Following Strong Results and Increased Guidance",
      "cleaned_body": "Carillon Tower Advisers, an investment management company, released its Carillon Eagle Growth Income Fund third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S 2462 chars",
      "cleaned_text": "AbbVie ABBV Surged Following Strong Results and Increased Guidance. Carillon Tower Advisers, an investment management company, released its Carillon Eagle Growth Income Fund third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S 2462 chars",
      "tokens": {
        "original": [
          "abbvie",
          "abbv",
          "surged",
          "following",
          "strong",
          "results",
          "and",
          "increased",
          "guidance",
          "carillon",
          "tower",
          "advisers",
          ",",
          "an",
          "investment",
          "management",
          "company",
          ",",
          "released",
          "its",
          "carillon",
          "eagle",
          "growth",
          "income",
          "fund",
          "third-quarter",
          "2025",
          "investor",
          "letter",
          ".",
          "a",
          "copy",
          "of",
          "the",
          "letter",
          "can",
          "be",
          "downloaded",
          "here",
          ".",
          "the",
          "s",
          "2462",
          "chars"
        ],
        "filtered": [
          "abbvie",
          "abbv",
          "surged",
          "following",
          "strong",
          "results",
          "increased",
          "guidance",
          "carillon",
          "tower",
          "advisers",
          ",",
          "investment",
          "management",
          "company",
          ",",
          "released",
          "carillon",
          "eagle",
          "growth",
          "income",
          "fund",
          "third-quarter",
          "2025",
          "investor",
          "letter",
          ".",
          "copy",
          "letter",
          "downloaded",
          ".",
          "2462",
          "chars"
        ],
        "lemmatized": [
          "abbvie",
          "abbv",
          "surge",
          "follow",
          "strong",
          "result",
          "increase",
          "guidance",
          "carillon",
          "tower",
          "adviser",
          ",",
          "investment",
          "management",
          "company",
          ",",
          "release",
          "carillon",
          "eagle",
          "growth",
          "income",
          "fund",
          "third-quarter",
          "2025",
          "investor",
          "letter",
          ".",
          "copy",
          "letter",
          "download",
          ".",
          "2462",
          "char"
        ]
      },
      "features": {
        "entities": {
          "PERSON": [
            "Carillon Tower Advisers",
            "Carillon Eagle Growth",
            "Income Fund"
          ],
          "ORGANIZATION": [
            "ABBV"
          ],
          "GPE": [
            "AbbVie",
            "Strong",
            "Guidance"
          ]
        },
        "financial_keywords": {
          "positive": [
            "surge",
            "strong",
            "growth"
          ],
          "negative": [],
          "neutral": [
            "release",
            "quarter"
          ]
        },
        "numbers": [
          "2025",
          "2462"
        ],
        "percentages": [],
        "dates": [],
        "top_words": [
          [
            "carillon",
            2
          ],
          [
            "letter",
            2
          ],
          [
            "abbvie",
            1
          ],
          [
            "abbv",
            1
          ],
          [
            "surge",
            1
          ],
          [
            "follow",
            1
          ],
          [
            "strong",
            1
          ],
          [
            "result",
            1
          ],
          [
            "increase",
            1
          ],
          [
            "guidance",
            1
          ]
        ],
        "stats": {
          "num_entities": 7,
          "num_positive_keywords": 3,
          "num_negative_keywords": 0,
          "num_neutral_keywords": 2,
          "num_numbers": 2,
          "num_percentages": 0,
          "num_dates": 0
        }
      },
      "stats": {
        "num_sentences": 4,
        "num_words": 45,
        "avg_words_per_sentence": 11.25,
        "num_unique_words": 39
      },
      "processed_at": "2025-11-14T03:28:53.231202",
      "preprocessing_version": "1.0",
      "article_id": "a0f4f945ded4faef",
      "title": "AbbVie (ABBV) Surged Following Strong Results and Increased Guidance",
      "description": "Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third-quarter 2025 investor letter. A copy of...",
      "body": "Carillon Tower Advisers, an investment management company, released its Carillon Eagle Growth &amp; Income Fund third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&… [+2462 chars]",
      "source": "Yahoo Entertainment",
      "source_api": "newsapi",
      "source_priority": 3,
      "url": "https://finance.yahoo.com/news/abbvie-abbv-surged-following-strong-141859611.html",
      "author": "Soumya Eswaran",
      "published_at": "2025-11-12T14:18:59Z",
      "scraped_at": "2025-11-13T22:21:10.044052",
      "ticker": "AAPL",
      "raw_text": "AbbVie (ABBV) Surged Following Strong Results and Increased Guidance Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third-quarter 2025 investor letter. A copy of... Carillon Tower Advisers, an investment management company, released its Carillon Eagle Growth &amp; Income Fund third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&… [+2462 chars]",
      "sentiment_score": null,
      "sentiment_label": null,
      "image": null,
      "category": null,
      "tickers_mentioned": [
        "ABBV"
      ],
      "ticker_confidence": {
        "ABBV": 80
      },
      "ticker_contexts": {},
      "is_duplicate": false,
      "duplicate_of": null,
      "similarity_score": 0.0
    }
  ],
  "metadata": {
    "preprocessing": {
      "cleaned": true,
      "tokenized": true,
      "lemmatized": true,
      "features_extracted": true
    },
    "fields_available": [
      "cleaned_title",
      "cleaned_body",
      "tokens (original, filtered, lemmatized)",
      "features (entities, financial_keywords, numbers, dates)",
      "tickers_mentioned",
      "ticker_contexts"
    ]
  }
}